Belatacept injection bulk supplier for pharma manufacturers

Belatacept Injection 250 mg/vial Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 250 mg/vial

Reference Brands: Nulojix(US)

Belatacept is a fusion protein that blocks CD80/CD86 on immune cells, preventing T-cell activation. It effectively reduces kidney transplant rejection, supports long-term graft survival, and decreases the need for intensive immunosuppressants. Benefits include targeted immunosuppression, fewer side effects, and improved quality of life for transplant recipients.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Belatacept, marketed as Nulojix, is approved in the US by the FDA and in the EU via EMA for rejection prevention in adult kidney transplant recipients. Regulatory approval requires comprehensive dossiers, including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality information, while the EMA ensures compliance with regional safety and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring proper regional adherence supports timely approval, safe use, and global availability, helping transplant patients achieve optimal long-term outcomes and graft survival worldwide.

Belatacept Injection — third party manufacturing & bulk supply

Belatacept Injection 250 mg/vial is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Belatacept Injection is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Belatacept Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Belatacept Injection →

Back to Listing

Frequently Asked Questions

Belatacept injection is listed as Injection in 250 mg/vial. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Belatacept injection is referenced against Nulojix(US). Reference brands are shown for identification only and remain the property of their respective trademark owners.